Laboratorios Farmaceuticos Rovi stock
ROVI.MCBMELaboratorios Farmaceuticos Rovi, S.A., HealthcareISIN ES0157261019
82Score 82 out of 100, Strong
Price and trend
59 / 100
Price history
+19% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.5% above it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 87).
The price is 18% below its 52-week high. Largest decline in 19 years: 67% (February 2008 to March 2009).
Chart figures for advanced users
- SMA 50$66.93
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$72.98
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)87
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$59.45
- The lowest closing price of the last twelve months.
- Resistance$94.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Laboratorios Farmaceuticos Rovi, S.A. belongs to the Drug Manufacturers (Specialty & Generic) industry (Spain) and, with a market value of $3.98B, is number 43 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $823.85M (down 2.7% year on year) and earnings of $155.62M (up 2.6%).
- For fiscal 2026, analysts expect on average revenue of $862.5M (up 4.7%) and adjusted earnings per share of $3.41 (up 12.9%).
Show more
- MEQIRI Score 82 out of 100 (Strong): rank 12 of 702 in Healthcare, median 53.
- The P/E is 17.5 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 25.2).
- Our model puts fair value at $102.41, with the price 24% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 20.1% a year since 2020.Growth 92
- High marginNet margin 24.8% over the last 12 months, Drug Manufacturers (Specialty & Generic) median 8.6%.Profitability 92
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 74
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and growth.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $78.78 and expensive above $146.30 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $120.55 (cash-flow model) and $84.27 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8%. At 9% the fair value would be $90.99, at 7% it would be $119.67.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.4% on the twelve months before. Revenue has grown strongly since 2006, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 61%, operating 23%, net 19%. Last 12 months: net 25%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 5 Nov 2026EPS reported $1.70
Analyst estimates
Analysts have raised their 2026 earnings estimate by 13.3% since 15 Oct 2026.
- Earnings per share
- $3.41+13.3%
- Revenue
- $862.5M+0.7%
- Earnings per share
- $3.63−0.3%
- Revenue
- $990.19M+0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.6%The overall guidance is maintained (revenue growth of low to mid single digits), while the outlook for heparins improved to a mid single digit decline instead of a high single digit decline.
“Consequently, we have improved our outlook for the low molecular weight heparins franchise and now expect sales to decline by a mid-single-digit percentage this year compared with our previous guidance of high single-digit decline.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Laboratorios Farmaceuticos Rovi
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 82
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Apotex HealthAPTX.TO $6.17B68
- Gland PharmaGLAND.NS $5.8B70
- Sumitomo Pharma4506.T $5.54B57
- Ipca LaboratoriesIPCALAB.NS $5.12B69
- Siegfried HoldingSFZN.SW $3.75B54
- Bausch Health CompaniesBHC $3.09B61
- HUTCHMED (China)HCM $2.65B45
- AlmirallALM.MC $2.6B45
ETFs that hold Laboratorios Farmaceuticos Rovi
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree Eurozone Quality Dividend Growth UCITS ETF EUR AccWTIM | 0.34% | 0.29% | €49.19M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.28% | 0.40% | €580.62M |
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.21% | 0.58% | €838.19M |
Show 5 more
| Amundi IBEX 35 UCITS ETF AccAMES | 0.21% | 0.30% | €942.58M |
| Xtrackers Spain UCITS ETF 1DXESD | 0.13% | 0.30% | €511.41M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.10% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.45B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.04% | 0.30% | €813.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Apr 2025)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.